PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been selected for the shortlist of the 5th Annual Vaccine Industry Excellence (ViE) Awards in the category of Best Therapeutic Vaccine (approved or in development) for its ADXS-HPV construct. The ViE awards, sponsored by Novartis Vaccines and Diagnostics, were created to recognize the accomplishments and contributions of companies and individuals in the vaccine industry over the previous 12 months.
